Darolutamide

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 513 publications

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol.

The DARO-flare trial: evaluating the impact of darolutamide on prostate-specific membrane antigen (PSMA) flare and its implications for imaging and staging of hormone-sensitive prostate cancer - study protocol.

Journal: BMJ open

Published: June 18, 2026

Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making.

Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making.

Journal: Expert review of clinical pharmacology

Published: May 19, 2026

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.

Journal: Current medical research and opinion

Published: April 23, 2026

Insurance Disparity in Novel Hormonal Therapy Initiation in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Medicare Advantage Versus Traditional Medicare.

Insurance Disparity in Novel Hormonal Therapy Initiation in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Medicare Advantage Versus Traditional Medicare.

Journal: JCO oncology practice

Published: April 23, 2026

Exploring the relationship between potential hepatotoxicity and novel hormonal therapies in prostate cancer: a systematic review and meta-analysis.

Exploring the relationship between potential hepatotoxicity and novel hormonal therapies in prostate cancer: a systematic review and meta-analysis.

Journal: BMC cancer

Published: April 19, 2026

Is there an optimal sequential order to androgen receptor axis therapeutics?

Is there an optimal sequential order to androgen receptor axis therapeutics?

Journal: Clinical advances in hematology & oncology : H&O

Published: April 17, 2026

Systemic Treatments in Men with De Novo Metastatic Prostate Cancer.

Systemic Treatments in Men with De Novo Metastatic Prostate Cancer.

Journal: The Urologic clinics of North America

Published: April 15, 2026

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01.

Journal: Future oncology (London, England)

Published: April 14, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology

Published: April 09, 2026

In Vitro and In Vivo Assessment of Darolutamide Encapsulated Lipid-Extruded PEGylated Liposomal Formulation.

In Vitro and In Vivo Assessment of Darolutamide Encapsulated Lipid-Extruded PEGylated Liposomal Formulation.

Journal: ACS applied bio materials

Published: April 08, 2026

Comparative fall risk of patients treated with novel androgen receptor antagonists in prostate cancer: a systematic review and meta-analysis.

Comparative fall risk of patients treated with novel androgen receptor antagonists in prostate cancer: a systematic review and meta-analysis.

Journal: BMC cancer

Published: March 19, 2026

Showing 1-12 of 513

Last Updated: 06/30/2026